GlaxoSmithKline Pharmaceuticals shares rose by 2.19% to ₹2,668.00 on Friday, backed by robust financial performance and bullish investor sentiment. According to reports from Moneycontrol, the stock, a constituent of the Nifty Midcap 150 index, experienced this upward movement at 2:33 pm on the NSE. The positive market response reflects strong investor confidence in the company's financial trajectory and upcoming quarterly results.
The company delivered strong first-quarter performance with consolidated net profit rising 15.69% year-on-year to ₹237.18 crore compared to ₹205.01 crore in the corresponding quarter last year. As reported by Business Standard, revenue from operations increased 16.55% to ₹938.44 crore from ₹805.17 crore in Q1 FY2026. The pharmaceutical company's EBITDA rose 25.8% year-on-year to ₹444.3 crore, while EBITDA margin expanded significantly to 47.35% from 43.86% in the corresponding quarter last year, demonstrating enhanced operational efficiency and improved profitability.
The company's growth was driven by strong performance across general medicines, vaccines and innovative medicines portfolios. According to CNBC TV18, brands including Augmentin, Ceftum and T-Bact maintained their positions, supported by scientific engagement with healthcare professionals, omnichannel execution and pricing actions. The respiratory portfolio continued to expand, with Nucala seeing higher patient adoption and Trelegy Ellipta gaining traction through new access pathways. The vaccines business recorded growth, led by private paediatric vaccines such as Infanrix Hexa and Fluarix Tetra, while demand for Shingrix improved in the adult vaccination segment.
Looking ahead, GSK Pharma announced significant developments in its pipeline. As reported by CNBC TV18, the company is preparing to launch Blenrep (belantamab mafodotin), a treatment for adults with relapsed or refractory multiple myeloma, in India. Additionally, Arexvy, its vaccine to prevent respiratory syncytial virus (RSV)-related lower respiratory tract disease in adults aged 60 years and above, as well as high-risk adults aged 50-59 years, has received marketing authorisation. Managing Director Bhushan Akshikar stated that the quarter's performance reflected broad-based growth across the company's general medicines, vaccines and innovative medicines portfolio, with GSK remaining focused on execution, technology investments and future product launches to support long-term growth.
The company's P/E ratio for March 2026 was 37.33, while the P/B ratio stood at 17.06. According to Moneycontrol analysis, the Return on Networth/Equity was 45.68% for March 2026, with the operating margin improving from 33.51% in March 2025 to 36.32% in March 2026. The rise in GSK Pharma's share price aligns with a very bullish investor sentiment observed as of July 31, 2026, with the strong financial performance and upcoming board meeting for Q1 results contributing to this positive market outlook. However, shares ended 0.02% lower at ₹2,655 on the NSE on August 3, ahead of the company's June quarter earnings announcement.
